Enliven Therapeutics director Scott Garland sells $606k in stock
Covered in this story
Analyst targets on Enliven Therapeutics Inc
- Guggenheim: $40.6 → $78 by Oct 2027 · Buy via Investing.com
- Morgan Stanley: $47 → $70 by Oct 2027 · Overweight via Investing.com
- JPMorgan: $46.2 → $75 by Oct 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ELVN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Enliven Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.